To determine if combination treatment could confer long-term immune memory formation, we performed a GL261 tumor rechallenge in long-term survivors (> 55days) that had received AAV6-CXCL9 plus anti-PD-1 ICB. The gene discussed is CXCL9; the disease is neoplasm.